Business, energy, technology, markets and global industry news from Business News Today

NMIBC

PharmaDeviceNews NMIBC
Representative image: Endoscopic bladder procedure scene highlighting UroGen Pharma’s UGN-501 clearance and the next-stage search for intravesical oncolytic virus therapy in non-muscle invasive bladder cancer.
Pharma & Biotech

Could UroGen Pharma’s oncolytic virus open the next chapter in bladder cancer therapy?

UroGen Pharma Ltd. (Nasdaq: URGN) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer. The clearance enables the urothelial cancer-focused biotechnology company to begin a planned Phase 1 trial of local intravesical administration, with patient enrollment expected to

Read More
Pharma & Biotech

ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize

Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.

Read More
Pharma & Biotech

Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy

UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.

Read More
Representative image of vial thawing in a clinical preparation setting, illustrating how Ferring Pharmaceuticals’ faster ADSTILADRIN thaw protocol could improve bladder cancer treatment workflow in BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground

FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.

Read More
Pharma & Biotech

Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation

ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.

Read More
Pharma & Biotech

EMA backs ANKTIVA for bladder cancer: What it means for EU patients and future immunotherapies

ImmunityBio Inc. has received a positive recommendation from the European Medicines Agency for conditional marketing authorization of its immunotherapy ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin for the treatment of BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ. The recommendation positions ANKTIVA as the first immunotherapy in the European Union for this indication,

Read More